The Paradox of Life Extension with Traditional Cost-Effectiveness Analysis: A Case Study with Duchenne Muscular Dystrophy
These results suggest that within a traditional CEA, delaying mortality decreases a DMD treatment's value estimate, countering society's values and norms for desired life extension in vulnerable populations. These limitations must be carefully considered when interpreting model results and highlight the need for applying other value assessment methodologies.
Authors
- Alexa C. Klimchak (ORCID: https://orcid.org/0000-0001-8196-7093)
- Katherine Gooch (ORCID: https://orcid.org/0009-0000-6382-614X)
- Lauren E. Sedita (ORCID: https://orcid.org/0000-0003-0899-1585)
- Daniel C. Malone (ORCID: https://orcid.org/0000-0002-5006-9394)
- EM Perfetto
Institutions
- University of Maryland, Baltimore (US)
- University of Utah (US)
- Sarepta Therapeutics (United States) (US)
Publication Details
- Journal
- Journal of health economics and outcomes research
- Published
- 2026-02-18
- DOI
- https://doi.org/10.36469/001c.156118
- Primary Topic
- Muscle Physiology and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sarepta Therapeutics